| Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.Influenza Other Respir Viruses | PMID 38890511PMC11187911 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.Cancer Med | PMID 38924353PMC11194683 | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.J Crohns Colitis | PMID 37942921PMC11140624 | 2024-May-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.N Engl J Med | PMID 38739079无 PMCID | 2024-May-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.Mol Cancer | PMID 38811992PMC11137956 | 2024-May-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.Blood Adv | PMID 38330179PMC11112604 | 2024-May-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.JAMA | PMID 38683596PMC11059055 | 2024-May-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.RMD Open | PMID 38806190PMC11138271 | 2024-May-28 | 0.95 | The study fails the oncology criterion as it is not a cancer trial. It also lacks the required time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis of such). | 待处理 |
| Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.BMJ | PMID 38806195无 PMCID | 2024-May-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.Lancet | PMID 38705160无 PMCID | 2024-May-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Rose geranium in sesame oil nasal spray to improve nasal vestibulitis symptoms: a randomized controlled trial.Support Care Cancer | PMID 38789656无 PMCID | 2024-May-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.BMC Cancer | PMID 38789924PMC11127459 | 2024-May-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis.Arthritis Res Ther | PMID 38790040PMC11127290 | 2024-May-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.Br J Ophthalmol | PMID 37669850PMC11137441 | 2024-May-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.J Med Genet | PMID 37940383PMC11137442 | 2024-May-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial).Trials | PMID 38773643PMC11106873 | 2024-May-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.Chin Med J (Engl) | PMID 38192233PMC11101224 | 2024-May-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.J Clin Oncol | PMID 38412399无 PMCID | 2024-May-20 | 0.95 | The study is a Phase III randomized trial in oncology patients with a drug intervention and an original result. However, it is ineligible because the primary endpoint (incidence of hand-foot syndrome) is a safety/tolerability outcome, not a time-to-event efficacy endpoint as required (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 待处理 |
| Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.J Clin Oncol | PMID 38422473PMC11107894 | 2024-May-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.Br J Dermatol | PMID 38470171无 PMCID | 2024-May-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.Blood | PMID 38457359PMC11143515 | 2024-May-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.N Engl J Med | PMID 38587247无 PMCID | 2024-May-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perioperative Nivolumab in Resectable Lung Cancer.N Engl J Med | PMID 38749033无 PMCID | 2024-May-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults.Clin Infect Dis | PMID 37992000PMC11093669 | 2024-May-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.Clin Infect Dis | PMID 38016021PMC11093671 | 2024-May-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study.J Neurol Neurosurg Psychiatry | PMID 38071574无 PMCID | 2024-May-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106.Blood Adv | PMID 38743412PMC11116995 | 2024-May-14 | 0.45 | Title and metadata indicate a randomized Phase III oncology trial with a drug intervention, but the abstract is not provided and no time-to-event signal (OS, PFS, DFS, HR, Kaplan-Meier) is detected in the provided metadata. Cannot confirm human subjects or that this is an original result report (vs. update, erratum, etc.). | 待处理 |
| Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials.Nat Commun | PMID 38744844PMC11094049 | 2024-May-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial.J Ethnopharmacol | PMID 38341113无 PMCID | 2024-May-10 | 0.90 | The trial is a randomized Phase III study in oncology patients with a drug intervention and reports original results. However, it is not eligible for the cohort because the primary and secondary endpoints are categorical response rates for chemotherapy-induced nausea and vomiting and quality-of-life scores, which are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS). The study lacks any Kaplan-Meier analysis, hazard ratio, or other time-to-event outcome. | 待处理 |
| Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.J Clin Oncol | PMID 38364196无 PMCID | 2024-May-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.J Clin Oncol | PMID 38452313PMC11095869 | 2024-May-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.Vaccine | PMID 38616438无 PMCID | 2024-May-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.Vaccine | PMID 38637211无 PMCID | 2024-May-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.Alzheimers Res Ther | PMID 38730496PMC11084061 | 2024-May-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.RMD Open | PMID 38724259PMC11086426 | 2024-May-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Haploidentical hematopoietic cell transplantation with or without an unrelated cord blood unit for adult acute myeloid leukemia: a multicenter, randomized, open-label, phase 3 trial.Signal Transduct Target Ther | PMID 38705885PMC11070414 | 2024-May-06 | 0.95 | The study is a Phase III randomized oncology trial with a primary time-to-event endpoint (OS) and original results, but the intervention is a transplant procedure (haploidentical and cord blood HCT) and does not involve a drug-containing intervention as defined by the adjudication rules. | 待处理 |
| RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial.Adv Respir Med | PMID 38804439PMC11130936 | 2024-May-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001.Neuro Oncol | PMID 38069666PMC11066939 | 2024-May-03 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.Neuro Oncol | PMID 38445964PMC11066938 | 2024-May-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.Antimicrob Agents Chemother | PMID 38587380PMC11064544 | 2024-May-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura.N Engl J Med | PMID 38692292无 PMCID | 2024-May-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase 3 Randomized Controlled Trial.Int J Radiat Oncol Biol Phys | PMID 37924987PMC11023796 | 2024-May-01 | 0.85 | The record is a secondary analysis of a Phase III RCT in oncology (prostate cancer) but does not report any of the required efficacy outcomes (survival, progression, recurrence, death, hazard, time-to-event). It reports on bone mineral density and fracture, which are not considered primary oncology efficacy outcomes for this adjudication. | 待处理 |
| Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.J Clin Oncol | PMID 38315944无 PMCID | 2024-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China.Diabetes | PMID 38320260PMC11043058 | 2024-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial.J Clin Oncol | PMID 38350047PMC11095877 | 2024-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.Am J Respir Crit Care Med | PMID 38354066PMC11092957 | 2024-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS).J Affect Disord | PMID 38378088无 PMCID | 2024-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.JAMA Oncol | PMID 38451492PMC10921349 | 2024-May-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 38483412PMC10941019 | 2024-May-01 | 0.95 | The trial is a Phase III randomized clinical trial in oncology with a primary patient-reported outcome endpoint and secondary time-to-event endpoints. However, the intervention is radiotherapy (a non-drug therapy), and no drug-containing intervention is described. Eligibility requires a drug-containing intervention, so the record is excluded. | 待处理 |
| Ventilatory Assistance Before Umbilical Cord Clamping in Extremely Preterm Infants: A Randomized Clinical Trial.JAMA Netw Open | PMID 38758557PMC11102017 | 2024-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |